Analytical Data
-
Gene name
MAGEF1
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HAY2
-
Expression Region
Met1~Trp307
-
Molecular Weight
40kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEF1, a member of the MAGE (Melanoma Antigen Gene) family, has garnered research interest due to its potential roles in cancer biology and immunology. Initially characterized for its expression in malignant tissues, particularly in melanoma, MAGEF1 is thought to play a role in tumorigenesis and immune evasion. Studies have suggested that MAGEF1 may be involved in regulating apoptosis and cell cycle progression, making it a key player in cancer proliferation. The protein's unique expression pattern also raises its potential as a target for cancer immunotherapy. Given its limited expression in normal tissues, MAGEF1 stands out as a promising biomarker for tumor diagnosis and a candidate for vaccine development. Advances in recombinant protein technology have enabled researchers to produce MAGEF1 in vitro, allowing for further exploration of its structural and functional properties. This progress opens avenues for developing MAGEF1-based therapeutic strategies, particularly in personalized medicine, where tumor-specific antigens are crucial for effective immune responses. Overall, ongoing research into MAGEF1 aims to deepen the understanding of its role in cancer and contribute to innovative approaches in cancer treatment.
